Whole-Body [
Female
Fluorodeoxyglucose F18
/ chemistry
Humans
Magnetic Resonance Imaging
/ methods
Male
Melanoma
/ diagnostic imaging
Middle Aged
Multimodal Imaging
/ methods
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography
/ methods
Positron-Emission Tomography
/ methods
Prospective Studies
Radiopharmaceuticals
/ chemistry
Whole Body Imaging
/ methods
Computed tomography
Distant metastasis
Magnetic resonance imaging
Melanoma
Positron emission tomography
[18F]FDG-PET
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
1
8
2019
medline:
3
6
2021
entrez:
1
8
2019
Statut:
ppublish
Résumé
To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[ We included patients with malignant melanoma who underwent a single injection [ Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma. Whole-body [
Identifiants
pubmed: 31363965
doi: 10.1007/s11307-019-01413-7
pii: 10.1007/s11307-019-01413-7
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
739-744Références
Tas F (2012) Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol 2012:647684
doi: 10.1155/2012/647684
Meier F, Will S, Ellwanger U et al (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147:62–70
doi: 10.1046/j.1365-2133.2002.04867.x
Gershenwald JE, Scolyer RA (2018) Ann Surg Oncol 25:2105
doi: 10.1245/s10434-018-6513-7
Pflugfelder A, Kochs C, Blum A et al (2013) Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 11:1–116
pubmed: 24028775
Wong ANM, McArthur GA, Hofman MS, Hicks RJ (2017) The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging 44:67–77
doi: 10.1007/s00259-017-3691-7
Boellaard R, Delgado-Bolton R, Oyen WJ et al (2015) FDG PET/CT: EANM procedure guidelines for tumor imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354
doi: 10.1007/s00259-014-2961-x
Heusch P, Nensa F, Schaarschmidt B et al (2015) Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging 42:42–48
doi: 10.1007/s00259-014-2885-5
Giraudo C, Raderer M, Karanikas G et al (2016)
doi: 10.1097/RLI.0000000000000218
Berzaczy D, Giraudo C, Haug AR et al (2017) Whole-body
doi: 10.1097/RLU.0000000000001753
Jeong JH, Cho IH, Kong EJ et al (2014) Evaluation of Dixon sequence on hybrid PET/MR compared with contrast-enhanced PET/CT for PET-positive lesions. Nucl Med Mol Imaging 48:26–32
doi: 10.1007/s13139-013-0240-6
Sekine T, Barbosa FG, Sah BR et al (2017) PET/MR outperforms PET/CT in suspected occult tumors. Clin Nucl Med 42:e88–e95
doi: 10.1097/RLU.0000000000001461
Afaq A, Fraioli F, Sidhu H et al (2017) Comparison of PET/MRI with PET/CT in the evaluation of disease status in lymphoma. Clin Nucl Med 42:e1–e7
doi: 10.1097/RLU.0000000000001344
Souvatzoglou M, Eiber M, Takei T et al (2013) Comparison of integrated whole-body [
doi: 10.1007/s00259-013-2467-y
Lee SM, Goo JM, Park CM et al (2016) Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT. Eur Radiol 26:3850–3857
doi: 10.1007/s00330-016-4255-0
Rauscher I, Eiber M, Fürst S et al (2014) PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. J Nucl Med 55:724–729
doi: 10.2967/jnumed.113.129247
Kulemann V, Schima W, Tamandl D et al (2011) Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol 79:e1–e6
doi: 10.1016/j.ejrad.2010.03.004
Mayerhoefer ME, Ba-Salamah A, Weber M et al (2013) Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumors of the upper abdomen. Eur Radiol 23:1978–1985
doi: 10.1007/s00330-013-2785-2
Melsaether AN, Raad RA, Pujara AC et al (2016) Comparison of whole-body (18)F FDG PET/MR imaging and whole-body
doi: 10.1148/radiol.2016151155
Eiber M, Takei T, Souvatzoglou M et al (2014) Performance of whole-body integrated
doi: 10.2967/jnumed.113.123646
Muehe AM, Theruvath AJ, Lai L, Aghighi M, Quon A, Holdsworth SJ, Wang J, Luna-Fineman S, Marina N, Advani R, Rosenberg J, Daldrup-Link HE (2018) How to provide gadolinium-free PET/MR cancer staging of children and young adults in less than 1 h: the Stanford Approach. Mol Imaging Biol 20:324–335
doi: 10.1007/s11307-017-1105-7